No Cover Image

Journal article 568 views 90 downloads

Effectiveness of the Strengthening Families Programme in the UK at preventing substance misuse in 10–14 year-olds: a pragmatic randomised controlled trial

Jeremy Segrott Orcid Logo, David Gillespie Orcid Logo, Mandy Lau Orcid Logo, Jo Holliday Orcid Logo, Simon Murphy Orcid Logo, David Foxcroft Orcid Logo, Kerenza Hood Orcid Logo, Jonathan Scourfield Orcid Logo, Ceri Phillips, Zoe Roberts, Heather Rothwell, Claire Hurlow, Laurence Moore Orcid Logo

BMJ Open, Volume: 12, Issue: 2, Start page: e049647

Swansea University Authors: Ceri Phillips, Claire Hurlow

  • 60738.pdf

    PDF | Version of Record

    © Author(s) (or their employer(s)) 2022. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license

    Download (1.58MB)

Check full text

DOI (Published version): 10.1136/bmjopen-2021-049647

Abstract

Objectives The Strengthening Families Programme 10–14 (SFP10-14) is a USA-developed universal group-based intervention aiming to prevent substance misuse by strengthening protective factors within the family. This study evaluated a proportionate universal implementation of the adapted UK version (SF...

Full description

Published in: BMJ Open
ISSN: 2044-6055 2044-6055
Published: BMJ 2022
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa60738
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: Objectives The Strengthening Families Programme 10–14 (SFP10-14) is a USA-developed universal group-based intervention aiming to prevent substance misuse by strengthening protective factors within the family. This study evaluated a proportionate universal implementation of the adapted UK version (SFP10-14UK) which brought together families identified as likely/not likely to experience/present challenges within a group setting.Design Pragmatic cluster-randomised controlled effectiveness trial, with families as the unit of randomisation and embedded process and economic evaluations.Setting The study took place in seven counties of Wales, UK.Participants 715 families (919 parents/carers, 931 young people) were randomised.Interventions Families randomised to the intervention arm received the SFP10-14 comprising seven weekly sessions. Families in intervention and control arms received existing services as normal.Outcome measures Primary outcomes were the number of occasions young people reported drinking alcohol in the last 30 days; and drunkenness during the same period, dichotomised as ‘never’ and ‘1–2 times or more’. Secondary outcomes examined alcohol/tobacco/substance behaviours including: cannabis use; weekly smoking (validated by salivary cotinine measures); age of alcohol initiation; frequency of drinking >5 drinks in a row; frequency of different types of alcoholic drinks; alcohol-related problems. Retention: primary analysis included 746 young people (80.1%) (alcohol consumption) and 732 young people (78.6%) (drunkenness).Results There was no evidence of statistically significant between-group differences 2 years after randomisation for primary outcomes (young people’s alcohol consumption in the last 30 days adjusted OR=1.11, 95% CI 0.72 to 1.71, p=0.646; drunkenness in the last 30 days adjusted OR=1.46, 95% CI 0.83 to 2.55, p=0.185). There were no statistically significant between-group differences for other substance use outcomes, or those relating to well-being/stress, and emotional/behavioural problems.Conclusions Previous evidence of effectiveness was not replicated. Findings highlight the importance of evaluating interventions when they are adapted for new settings.
College: Faculty of Medicine, Health and Life Sciences
Funders: Funding of £2.1 million from the National Prevention Research Initiative, managed by the Medical Research Council (award G0802128), included approximately £650 000 implementation costs. The NPRI funding partners are Alzheimer’s Research Trust; Alzheimer’s Society; Biotechnology and Biological Sciences Research Council; British Heart Foundation; Cancer Research UK; Chief Scientist Office, Scottish Government Health Directorate; Department of Health; Diabetes UK; Economic and Social Research Council; Engineering and Physical Sciences Research Council; Health and Social Care Research and Development Office for Northern Ireland; Medical Research Council; the Stroke Association; Welsh Government; and World Cancer Research Fund. A representative from the study funders was a member of the trial’s independent trial steering committee. The Welsh Government provided approximately £675 000 of partnership funding to cover the cost of implementation in three trial areas, and the associated training and support provided by the Cardiff Strengthening Families Programme team. Further support from the Welsh Government provided £208 000 to cover programme delivery in six trial sites from August 2011 to July 2012. The Cardiff Strengthening Families Programme team also provided financial support for programme delivery and trial recruitment in schools. At the time of the study, DECIPHer was a UKCRC Public Health Research Centre of Excellence. Funding from the British Heart Foundation, Cancer Research UK, Economic and Social Research Council (RES-590-28-0005), Medical Research Council, the Welsh Government and the Wellcome Trust (WT087640MA), under the auspices of the UK Clinical Research Collaboration, is gratefully acknowledged. DECIPHer funding has supported JSe and JH’s input into the trial. The centre is now funded by the Welsh Government through Health and Care Research Wales. LM is supported by the Medical Research Council (MC_UU_00022/1) and the Chief Scientist Office (SPHSU16). The Centre for Trials Research is funded by Health and Care Research Wales and Cancer Research UK.
Issue: 2
Start Page: e049647

Similar Items